Replies to post #238706 on Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

You are exactly right. It is this confusion that I feel doesn't pave a solid path for oral labeling both by a 3rd party panel or internally at the FDA. I could be completely wrong, but I think it easily leaves the door open for the FDA to deny labeling here.

[IB_]

"ELTP 2 bead antagonist ADF tech will easily qualify for IV, snorting, and chewing ADF label for every opioid agonist with any time-release characteristic. No known company is within 10 years of marketing an effective overdose ADF."

What about immediate-release such as SequestOx ???????????????????

Thanks 'WeeZuhl',

IB_